Peptides for fatty liver FAQ

Run them as parallel treatment arms with vehicle controls, not sequentially. Cross-contamination of metabolic effects is a real risk. AOD-9604's lipolytic effects persist for 48–72 hours after the last dose, meaning a washout period between peptides would need to be at least one week. Parallel arms eliminate this issue and allow direct statistical comparison. Make sure your sample size per group accounts for the variability in each peptide's response. GHRP-2 shows higher inter-subject variability (CV ~25%) than AOD-9604 or MOTS-C (CV ~15%) due to individual differences in pituitary GH reserve.

Switch peptides based on mechanism, not dose. If AOD-9604 shows no hepatic fat reduction after four weeks, increasing the dose won't help. The limiting factor is likely inadequate adipose lipolysis reaching the liver, which means the model's lipid accumulation is driven by hepatocyte-intrinsic mechanisms (de novo lipogenesis or impaired fatty acid oxidation) rather than adipose delivery. In that case, MOTS-C is the logical next step because it targets hepatocyte mitochondria directly. We've seen research teams waste six months dose-escalating a mechanistically mismatched peptide when switching compounds would have clarified the pathway in two experiments.

Verify reconstitution technique and peptide purity first. The single most common reason for failed replication in peptide research is reconstitution error. Injecting air into the vial during solution withdrawal creates positive pressure that draws contaminants back through the needle on subsequent draws. This degrades the peptide over multiple doses. If you're using a supplier without third-party purity verification (HPLC with UV detection at 214 nm showing ≥98% purity), that's the second most likely failure point. Published studies typically use pharmaceutical-grade peptides with batch certificates. Research-grade peptides without documentation introduce uncontrolled variables.

Switch to twice-daily dosing and verify gut permeability is actually elevated in your model. BPC-157's hepatoprotective mechanism depends on gut-liver axis inflammation. If baseline intestinal permeability is normal (measured via lactulose/mannitol ratio or FITC-dextran assay), BPC-157 won't produce measurable hepatic effects because the upstream inflammatory driver isn't present. Models using high-fat diet alone without gut barrier compromise may require addition of low-dose lipopolysaccharide or fructose to induce the intestinal permeability that makes BPC-157's mechanism relevant.

Verify dosing timing relative to feeding windows. AOD-9604's lipolytic effects are amplified during fasting states when insulin levels are low and hepatocytes can shift from lipogenesis to beta-oxidation. Administering the peptide immediately post-feeding or during high-insulin states blunts its hepatic lipid reduction capacity even when systemic fat loss is observable. Optimal protocols administer AOD-9604 during the early fasting window (12–16 hours post-feeding) when hepatocytes are primed for fatty acid oxidation.

Increase dosing frequency to maintain sustained AMPK activation. MOTS-c's half-life means three-times-weekly dosing may produce gaps in mitochondrial signalling that allow hepatic lipogenesis to continue between doses. Studies showing the strongest hepatic lipid reduction use daily or every-other-day administration rather than the standard three-times-weekly protocol, particularly in models with severe baseline mitochondrial dysfunction where hepatocyte oxidative capacity is profoundly impaired.

Sequence peptides by mechanism rather than administering all simultaneously. Start with BPC-157 to reduce baseline hepatic inflammation over 4–6 weeks, allowing damaged hepatocytes to stabilize. Introduce thymosin beta-4 once inflammatory markers (serum ALT, AST) normalize to address underlying fibrotic signaling without competing for receptor binding. AOD-9604 can be layered in during the stabilization phase since its lipolytic mechanism operates independently of inflammation pathways. However, monitor for excessive lipid mobilization, which can transiently worsen hepatic lipid load if mitochondrial oxidation capacity is overwhelmed.

Plan for peptide degradation and batch consistency. No reconstituted peptide remains stable beyond 28 days regardless of storage conditions. Lyophilized reserves must be maintained for studies exceeding one month. Batch-to-batch variability in commercial peptides can introduce confounding variables; Real Peptides maintains synthesis lot tracking to ensure researchers can source identical compound profiles across multi-month studies, eliminating a major source of experimental inconsistency.

Verify peptide integrity first. Request HPLC and mass spec analysis from your supplier. We've seen research teams attribute null results to ineffective compounds when the actual issue was <90% purity or incorrect amino acid sequencing. Second, confirm storage conditions: peptides stored above 8°C for even 24 hours can denature irreversibly. Third, verify dosing accuracy using proper reconstitution calculations. Many protocols fail because researchers used volumetric dosing without accounting for peptide concentration per vial.